Edwards Lifesciences (EW) Competitors

$79.07 +1.90 (+2.46%)

As of 10:48 AM Eastern

EW vs. HSIC, AMN, ISRG, ABT, and SYK

Should you be buying Edwards Lifesciences stock or one of its competitors? The main competitors of Edwards Lifesciences include Henry Schein (HSIC), AMN Healthcare Services (AMN), Intuitive Surgical (ISRG), Abbott Laboratories (ABT), and Stryker (SYK). These companies are all part of the "medical" sector.

How does Edwards Lifesciences compare to Henry Schein?

Henry Schein (NASDAQ:HSIC) and Edwards Lifesciences (NYSE:EW) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

Edwards Lifesciences has lower revenue, but higher earnings than Henry Schein. Henry Schein is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Henry Schein	$13.18B	0.60	$398M	$3.31	20.99
Edwards Lifesciences	$6.07B	7.49	$1.07B	$1.88	41.95

Henry Schein has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market. Comparatively, Edwards Lifesciences has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market.

Edwards Lifesciences has a net margin of 17.39% compared to Henry Schein's net margin of 2.95%. Henry Schein's return on equity of 15.44% beat Edwards Lifesciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Henry Schein	2.95%	15.44%	5.53%
Edwards Lifesciences	17.39%	15.19%	11.71%

Henry Schein presently has a consensus price target of $86.83, suggesting a potential upside of 24.96%. Edwards Lifesciences has a consensus price target of $95.65, suggesting a potential upside of 21.27%. Given Henry Schein's higher possible upside, equities research analysts plainly believe Henry Schein is more favorable than Edwards Lifesciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Henry Schein	1 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.36
Edwards Lifesciences	0 Sell rating(s)	9 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.79

In the previous week, Henry Schein had 9 more articles in the media than Edwards Lifesciences. MarketBeat recorded 19 mentions for Henry Schein and 10 mentions for Edwards Lifesciences. Edwards Lifesciences' average media sentiment score of 1.24 beat Henry Schein's score of 0.58 indicating that Edwards Lifesciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Henry Schein	4 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Edwards Lifesciences	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

96.6% of Henry Schein shares are owned by institutional investors. Comparatively, 79.5% of Edwards Lifesciences shares are owned by institutional investors. 0.9% of Henry Schein shares are owned by company insiders. Comparatively, 0.3% of Edwards Lifesciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Edwards Lifesciences beats Henry Schein on 10 of the 17 factors compared between the two stocks.

How does Edwards Lifesciences compare to AMN Healthcare Services?

AMN Healthcare Services (NYSE:AMN) and Edwards Lifesciences (NYSE:EW) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

Edwards Lifesciences has higher revenue and earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AMN Healthcare Services	$2.73B	0.40	-$95.70M	-$0.87	N/A
Edwards Lifesciences	$6.07B	7.49	$1.07B	$1.88	41.95

AMN Healthcare Services has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market. Comparatively, Edwards Lifesciences has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market.

Edwards Lifesciences has a net margin of 17.39% compared to AMN Healthcare Services' net margin of -0.95%. AMN Healthcare Services' return on equity of 18.01% beat Edwards Lifesciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AMN Healthcare Services	-0.95%	18.01%	5.19%
Edwards Lifesciences	17.39%	15.19%	11.71%

AMN Healthcare Services presently has a consensus price target of $23.50, suggesting a potential downside of 17.65%. Edwards Lifesciences has a consensus price target of $95.65, suggesting a potential upside of 21.27%. Given Edwards Lifesciences' stronger consensus rating and higher possible upside, analysts plainly believe Edwards Lifesciences is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AMN Healthcare Services	2 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.44
Edwards Lifesciences	0 Sell rating(s)	9 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.79

In the previous week, AMN Healthcare Services had 7 more articles in the media than Edwards Lifesciences. MarketBeat recorded 17 mentions for AMN Healthcare Services and 10 mentions for Edwards Lifesciences. Edwards Lifesciences' average media sentiment score of 1.24 beat AMN Healthcare Services' score of 0.69 indicating that Edwards Lifesciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AMN Healthcare Services	4 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Edwards Lifesciences	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.2% of AMN Healthcare Services shares are owned by institutional investors. Comparatively, 79.5% of Edwards Lifesciences shares are owned by institutional investors. 1.1% of AMN Healthcare Services shares are owned by company insiders. Comparatively, 0.3% of Edwards Lifesciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Edwards Lifesciences beats AMN Healthcare Services on 13 of the 17 factors compared between the two stocks.

How does Edwards Lifesciences compare to Intuitive Surgical?

Edwards Lifesciences (NYSE:EW) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment.

Edwards Lifesciences currently has a consensus price target of $95.65, indicating a potential upside of 21.27%. Intuitive Surgical has a consensus price target of $581.91, indicating a potential upside of 35.70%. Given Intuitive Surgical's higher probable upside, analysts plainly believe Intuitive Surgical is more favorable than Edwards Lifesciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edwards Lifesciences	0 Sell rating(s)	9 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.79
Intuitive Surgical	1 Sell rating(s)	7 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.65

79.5% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 83.6% of Intuitive Surgical shares are held by institutional investors. 0.3% of Edwards Lifesciences shares are held by insiders. Comparatively, 0.6% of Intuitive Surgical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Edwards Lifesciences has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, Intuitive Surgical has a beta of 1.51, suggesting that its share price is 51% more volatile than the broader market.

In the previous week, Intuitive Surgical had 26 more articles in the media than Edwards Lifesciences. MarketBeat recorded 36 mentions for Intuitive Surgical and 10 mentions for Edwards Lifesciences. Edwards Lifesciences' average media sentiment score of 1.24 beat Intuitive Surgical's score of 1.20 indicating that Edwards Lifesciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edwards Lifesciences	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Intuitive Surgical	28 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Intuitive Surgical has higher revenue and earnings than Edwards Lifesciences. Edwards Lifesciences is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edwards Lifesciences	$6.07B	7.49	$1.07B	$1.88	41.95
Intuitive Surgical	$10.06B	15.09	$2.86B	$8.25	51.98

Intuitive Surgical has a net margin of 28.15% compared to Edwards Lifesciences' net margin of 17.39%. Intuitive Surgical's return on equity of 15.98% beat Edwards Lifesciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edwards Lifesciences	17.39%	15.19%	11.71%
Intuitive Surgical	28.15%	15.98%	14.07%

Summary

Intuitive Surgical beats Edwards Lifesciences on 14 of the 17 factors compared between the two stocks.

How does Edwards Lifesciences compare to Abbott Laboratories?

Edwards Lifesciences (NYSE:EW) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment.

Edwards Lifesciences currently has a consensus price target of $95.65, indicating a potential upside of 21.27%. Abbott Laboratories has a consensus price target of $119.43, indicating a potential upside of 43.02%. Given Abbott Laboratories' stronger consensus rating and higher probable upside, analysts plainly believe Abbott Laboratories is more favorable than Edwards Lifesciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edwards Lifesciences	0 Sell rating(s)	9 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.79
Abbott Laboratories	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88

79.5% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 75.2% of Abbott Laboratories shares are held by institutional investors. 0.3% of Edwards Lifesciences shares are held by insiders. Comparatively, 0.5% of Abbott Laboratories shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Edwards Lifesciences has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, Abbott Laboratories has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market.

In the previous week, Abbott Laboratories had 24 more articles in the media than Edwards Lifesciences. MarketBeat recorded 34 mentions for Abbott Laboratories and 10 mentions for Edwards Lifesciences. Edwards Lifesciences' average media sentiment score of 1.24 beat Abbott Laboratories' score of 0.98 indicating that Edwards Lifesciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edwards Lifesciences	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abbott Laboratories	19 Very Positive mention(s)	7 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

Abbott Laboratories has higher revenue and earnings than Edwards Lifesciences. Abbott Laboratories is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edwards Lifesciences	$6.07B	7.49	$1.07B	$1.88	41.95
Abbott Laboratories	$44.33B	3.28	$6.52B	$3.57	23.39

Edwards Lifesciences has a net margin of 17.39% compared to Abbott Laboratories' net margin of 13.90%. Abbott Laboratories' return on equity of 17.62% beat Edwards Lifesciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edwards Lifesciences	17.39%	15.19%	11.71%
Abbott Laboratories	13.90%	17.62%	10.01%

Summary

Abbott Laboratories beats Edwards Lifesciences on 9 of the 17 factors compared between the two stocks.

How does Edwards Lifesciences compare to Stryker?

Edwards Lifesciences (NYSE:EW) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

Edwards Lifesciences has a net margin of 17.39% compared to Stryker's net margin of 13.20%. Stryker's return on equity of 23.42% beat Edwards Lifesciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edwards Lifesciences	17.39%	15.19%	11.71%
Stryker	13.20%	23.42%	11.04%

Edwards Lifesciences has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market. Comparatively, Stryker has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market.

Edwards Lifesciences currently has a consensus price target of $95.65, indicating a potential upside of 21.27%. Stryker has a consensus price target of $395.48, indicating a potential upside of 37.37%. Given Stryker's higher probable upside, analysts clearly believe Stryker is more favorable than Edwards Lifesciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edwards Lifesciences	0 Sell rating(s)	9 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.79
Stryker	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, Stryker had 12 more articles in the media than Edwards Lifesciences. MarketBeat recorded 22 mentions for Stryker and 10 mentions for Edwards Lifesciences. Edwards Lifesciences' average media sentiment score of 1.24 beat Stryker's score of 0.88 indicating that Edwards Lifesciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edwards Lifesciences	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stryker	12 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

79.5% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 77.1% of Stryker shares are held by institutional investors. 0.3% of Edwards Lifesciences shares are held by insiders. Comparatively, 4.6% of Stryker shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Stryker has higher revenue and earnings than Edwards Lifesciences. Stryker is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edwards Lifesciences	$6.07B	7.49	$1.07B	$1.88	41.95
Stryker	$25.12B	4.39	$3.25B	$8.64	33.32

Summary

Edwards Lifesciences beats Stryker on 9 of the 16 factors compared between the two stocks.

Get Edwards Lifesciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EW vs. The Competition

Export

Metric	Edwards Lifesciences	MED INSTRUMENTS Industry	Medical Sector	NYSE Exchange
Market Cap	$45.47B	$6.77B	$6.21B	$22.77B
Dividend Yield	N/A	1.72%	2.78%	4.03%
P/E Ratio	42.00	48.49	20.65	28.62
Price / Sales	7.49	61.31	543.19	103.86
Price / Cash	28.04	25.20	27.81	19.21
Price / Book	4.43	6.58	9.66	4.60
Net Income	$1.07B	$158.34M	$3.54B	$1.07B
7 Day Performance	-4.91%	-0.87%	-0.50%	-0.98%
1 Month Performance	1.31%	4.79%	5.73%	3.02%
1 Year Performance	5.67%	-3.23%	38.63%	24.10%

Edwards Lifesciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EW Edwards Lifesciences	4.4259 of 5 stars	$79.07 +2.5%	$95.65 +21.0%	+4.5%	$45.56B	$6.07B	42.09	16,000	Positive News
HSIC Henry Schein	3.8147 of 5 stars	$72.02 -2.6%	$87.75 +21.8%	+0.5%	$8.48B	$13.18B	22.02	25,000	Earnings Report Gap Up High Trading Volume
AMN AMN Healthcare Services	1.3283 of 5 stars	$20.76 -1.7%	$22.64 +9.0%	+38.4%	$816.10M	$2.73B	N/A	2,664	Earnings Report Analyst Forecast
ISRG Intuitive Surgical	4.293 of 5 stars	$452.35 -1.2%	$581.91 +28.6%	-21.7%	$162.13B	$10.06B	54.83	17,021	Trending News Insider Trade
ABT Abbott Laboratories	4.9612 of 5 stars	$87.59 -2.1%	$119.43 +36.4%	-38.1%	$155.82B	$44.33B	24.53	115,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:EW) was last updated on 5/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Edwards Lifesciences (EW) Competitors

EW vs. HSIC, AMN, ISRG, ABT, and SYK

How does Edwards Lifesciences compare to Henry Schein?

Summary

How does Edwards Lifesciences compare to AMN Healthcare Services?

Summary

How does Edwards Lifesciences compare to Intuitive Surgical?

Summary

How does Edwards Lifesciences compare to Abbott Laboratories?

Summary

How does Edwards Lifesciences compare to Stryker?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EW vs. The Competition

Edwards Lifesciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Edwards Lifesciences (EW) Competitors

EW vs. HSIC, AMN, ISRG, ABT, and SYK

How does Edwards Lifesciences compare to Henry Schein?

Which has higher valuation and earnings, HSIC or EW?

Which has more volatility & risk, HSIC or EW?

Is HSIC or EW more profitable?

Do analysts prefer HSIC or EW?

Does the media refer more to HSIC or EW?

Do insiders and institutionals hold more shares of HSIC or EW?

Summary

How does Edwards Lifesciences compare to AMN Healthcare Services?

Which has higher valuation and earnings, AMN or EW?

Which has more volatility & risk, AMN or EW?

Is AMN or EW more profitable?

Do analysts prefer AMN or EW?

Does the media refer more to AMN or EW?

Do insiders and institutionals hold more shares of AMN or EW?

Summary

How does Edwards Lifesciences compare to Intuitive Surgical?

Do analysts recommend EW or ISRG?

Do institutionals and insiders hold more shares of EW or ISRG?

Which has more volatility & risk, EW or ISRG?

Does the media prefer EW or ISRG?

Which has better earnings & valuation, EW or ISRG?

Is EW or ISRG more profitable?

Summary

How does Edwards Lifesciences compare to Abbott Laboratories?

Do analysts recommend EW or ABT?

Do institutionals and insiders hold more shares of EW or ABT?

Which has more volatility & risk, EW or ABT?

Does the media prefer EW or ABT?

Which has better earnings & valuation, EW or ABT?

Is EW or ABT more profitable?

Summary

How does Edwards Lifesciences compare to Stryker?

Is EW or SYK more profitable?

Which has more risk & volatility, EW or SYK?

Do analysts prefer EW or SYK?

Does the media favor EW or SYK?

Do insiders & institutionals hold more shares of EW or SYK?

Which has stronger earnings and valuation, EW or SYK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EW vs. The Competition

Edwards Lifesciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools